These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 7507155)

  • 21. The hydroxylamine of sulfamethoxazole synergizes with FK506 and cyclosporin A, inhibiting T-cell proliferation.
    Hess DA; Bird IA; Almawi WY; Rieder MJ
    J Pharmacol Exp Ther; 1997 Apr; 281(1):540-8. PubMed ID: 9103542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Categorizing receptor-signaling pathways with FK 506 and rapamycin.
    Hultsch T; Hohman RJ
    Transplant Proc; 1991 Dec; 23(6):2961-3. PubMed ID: 1721328
    [No Abstract]   [Full Text] [Related]  

  • 23. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin.
    Dumont FJ; Staruch MJ; Koprak SL; Melino MR; Sigal NH
    J Immunol; 1990 Jan; 144(1):251-8. PubMed ID: 1688572
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative effects of FK-506, rapamycin and cyclosporin A, on the in vitro differentiation of dorsal root ganglia explants and septal cholinergic neurons.
    Carreau A; Gueugnon J; Benavides J; Vigé X
    Neuropharmacology; 1997; 36(11-12):1755-62. PubMed ID: 9517448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of the immunosuppressant FK-506 on alternate pathways of T cell activation.
    Bierer BE; Schreiber SL; Burakoff SJ
    Eur J Immunol; 1991 Feb; 21(2):439-45. PubMed ID: 1705513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclosporin A, rapamycin and FK506 decrease prolactin release from rat pituitary cells in primary culture.
    Wera S; Zheng L; Hooghe-Peters EL; Belayew A; Martial JA; Velkeniers B
    Endocr Res; 1995 Aug; 21(3):623-33. PubMed ID: 7588431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms of action of immunosuppressive agents: cyclosporin A, FK506, and rapamycin.
    Bierer BE
    Proc Assoc Am Physicians; 1995 Apr; 107(1):28-40. PubMed ID: 8630742
    [No Abstract]   [Full Text] [Related]  

  • 28. The actions of cyclosporin A and FK506 on T-lymphocyte activation.
    Mattila PS
    Biochem Soc Trans; 1996 Feb; 24(1):45-9. PubMed ID: 8674715
    [No Abstract]   [Full Text] [Related]  

  • 29. Rapamycin (sirolimus) inhibits proliferating cell nuclear antigen expression and blocks cell cycle in the G1 phase in human keratinocyte stem cells.
    Javier AF; Bata-Csorgo Z; Ellis CN; Kang S; Voorhees JJ; Cooper KD
    J Clin Invest; 1997 May; 99(9):2094-9. PubMed ID: 9151781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of dexamethasone, cyclosporine, and rapamycin on T-lymphocyte proliferation in vitro: comparison of cells from patients with glucocorticoid-sensitive and glucocorticoid-resistant chronic asthma.
    Haczku A; Alexander A; Brown P; Assoufi B; Li B; Kay AB; Corrigan C
    J Allergy Clin Immunol; 1994 Feb; 93(2):510-9. PubMed ID: 8120277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FK 506, rapamycin, and cyclosporine: effects on IL-4 and IL-10 mRNA levels in a T-helper 2 cell line.
    Wang SC; Zeevi A; Jordan ML; Simmons RL; Tweardy DJ
    Transplant Proc; 1991 Dec; 23(6):2920-2. PubMed ID: 1721312
    [No Abstract]   [Full Text] [Related]  

  • 32. Inhibition of human immunodeficiency virus and growth of infected T cells by the immunosuppressive drugs cyclosporin A and FK 506.
    Karpas A; Lowdell M; Jacobson SK; Hill F
    Proc Natl Acad Sci U S A; 1992 Sep; 89(17):8351-5. PubMed ID: 1381509
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential anti-inflammatory effects of immunosuppressive drugs: cyclosporin, rapamycin and FK-506 on inducible nitric oxide synthase, nitric oxide, cyclooxygenase-2 and PGE2 production.
    Attur MG; Patel R; Thakker G; Vyas P; Levartovsky D; Patel P; Naqvi S; Raza R; Patel K; Abramson D; Bruno G; Abramson SB; Amin AR
    Inflamm Res; 2000 Jan; 49(1):20-6. PubMed ID: 10778917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Augmentation of T-cell apoptosis by immunosuppressive agents.
    Takahashi K; Reynolds M; Ogawa N; Longo DL; Burdick J
    Clin Transplant; 2004; 18 Suppl 12():72-5. PubMed ID: 15217412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-inflammatory effect of FK-506 on human skin mast cells.
    de Paulis A; Stellato C; Cirillo R; Ciccarelli A; Oriente A; Marone G
    J Invest Dermatol; 1992 Dec; 99(6):723-8. PubMed ID: 1281861
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular mechanisms of new immunosuppressants.
    Halloran PF
    Clin Transplant; 1996 Feb; 10(1 Pt 2):118-23. PubMed ID: 8680047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of T and B lymphocyte proliferation by rapamycin.
    Kay JE; Kromwel L; Doe SE; Denyer M
    Immunology; 1991 Apr; 72(4):544-9. PubMed ID: 1709916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Levels of cyclosporin in epidermis of treated psoriasis patients differentially inhibit growth of keratinocytes cultured in serum free versus serum containing media.
    Fisher GJ; Duell EA; Nickoloff BJ; Annesley TM; Kowalke JK; Ellis CN; Voorhees JJ
    J Invest Dermatol; 1988 Aug; 91(2):142-6. PubMed ID: 2456356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis.
    Trautmann A; Akdis M; Schmid-Grendelmeier P; Disch R; Bröcker EB; Blaser K; Akdis CA
    J Allergy Clin Immunol; 2001 Nov; 108(5):839-46. PubMed ID: 11692113
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo immunopharmacology of the macrolides FK 506 and rapamycin: toward the era of rational immunosuppressive drug discovery, development, and use.
    Morris RE
    Transplant Proc; 1991 Dec; 23(6):2722-4. PubMed ID: 1721257
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.